Have questions for our experts or want more information?
Contact Us Today
Webinar Overview: A New Scalable System for In Vitro Liver Testing
Drug-induced liver injury (DILI) is a leading cause of clinical trial attrition and post-marketing drug withdrawal, often driven by mechanisms that emerge only after repeated or long-term exposure. Although hepatotoxicity risk is typically assessed early using in vitro human liver models, primary human hepatocytes rapidly lose differentiation and function, which limits their effectiveness for chronic toxicity and DDI evaluation.
This webinar explores next-generation in vitro human liver models that allow for longer experiments and present an improved in vitro primary hepatocyte system maintaining functional stability over several weeks, not hours or days. ADME and DMPK scientists, nonclinical toxicologists, and researchers involved in nonclinical toxicity testing and de-risking efforts will learn valuable information on how these next-generation systems overcome the limitations of traditional models and enable more reliable predictions for your research.
View this webinar for a discussion on:
- The importance of long-term incubation systems in hepatotoxicity and DILI assessment
- Key strengths and limitations of commonly used in vitro human liver models
- How long-term data using scalable 2D systems can support extended incubation without added complexity
- Practical considerations for choosing between 2D or 3D models based on study goals
Scientific Moderator
Noémi Szili, PhD
Product Manager, DMPK
Charles River
Webinar Presenters
Zsuzsanna Gáborik, PhD
Associate Director, RnD
Charles River
Johanna Pacsuta
Research Scientist II, RnD
Charles River